| Parameters |
PR Group (n=12) |
SR Group (n=11) |
P value |
| Mean |
Median |
Mean |
Median |
| R (min) |
4.8 ± 2.21 |
5 [3.7, 5.9] |
4.9 ± 1.69 |
5.2 [3.8, 5.4] |
1.0 |
| SP (min) |
3.8 ± 1.86 |
4.3 [2.6, 4.8] |
3.4 ± 1.88 |
4.2 [2.8, 4.2] |
0.41 |
| D (min) |
1.1 ± 0.75 |
0.9 [0.5, 1.6] |
1.4 ± 1.42 |
0.8 [0.6, 1.2] |
0.82 |
| K (mm) |
2.0 ± 0.45 |
2.2 [1.7, 2.2] |
1.9 ± 0.84 |
1.6 [1.3, 2.6] |
0.45 |
| MA (mm) |
71.9 ± 5.66 |
72.1 [67.5, 75] |
68.7 ± 7.88 |
70.5 [66.3, 73.9] |
0.60 |
| α (°) |
61.8 ± 6.30 |
60.7 [57.8, 67.5] |
62.4 ± 11.55 |
67.4 [55.4, 70.4] |
0.55 |
| G (K dynes/cm2) |
12.2 ± 5.90 |
10.9 [9.7, 15.1] |
11.9 ± 3.73 |
13.4 [9.8, 14.4] |
0.94 |
Data are presented as mean ± SD and median [1st Quartile, 3rd Quartile]. Two-tailed
P value determined using Mann-Whitney U test. There were no statistically significant
differences between the two groups. SD = Standard Deviation; PR = propofol/
remifentanyl; SR = sevoflurane/remifentanyl |
Table 2b: Postoperative TEG® Data.
This table provides the preoperative TEG® PM™ measurements for both the PR
and SR groups. These measurements include G (overall clot strength), TEG® MA
(maximum clot strength), MA Activator (maximum clot strength of activator added),
ADP MA (maximum contribution of adenosine diphosphate channel to clot strength),
AA MA (maximum contribution of arachidonic acid channel to clot strength), ADP
Inhibition (percentage of ADP receptors inhibited), AA Inhibition (percentage of AA
receptors inhibited), ADP Aggregation (percentage of ADP aggregation), and AA
Aggregation (percentage of AA aggregation). |
